Superworth

Coherus Oncology price to free cash flow CHRS

Market value divided by free cash flow over the last twelve months, since 2020.

Today, Oct 23, 2026
n/m
not a meaningful number
Last meaningful
0.7×
Jul 2026
7-year median
9.9×
7-year range
0.7× to 51.7×
Peer median
16.7×

Coherus Oncology's price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Jul 2026, at 0.7×.

On the days it had one over the last 7 years, its median was 9.9×, from 0.7× in Jun 2026 to 51.7× in Mar 2020.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far0.7×0.7×0.8×
2025n/m a value too high to mean anything
2024n/m a value too high to mean anything
2023n/m a value too high to mean anything
202220.5×19.8×24.4×
202126.5×6.9×30.9×
20209.5×8.5×51.7×

Against its peers

Companies in Healthcare nearest Coherus Oncology's size, closest first, today.

CompanyPrice to free cash flow
CHRSCoherus Oncologyn/m
PDEXPro DEX29.5×
PLXProtalix BioTherapeutics26.8×
NATRNatures Sunshine Products11.8×
ELMDElectromed26.2×
UTMDUtah Medical Products20.6×
KEQUKewaunee Scientific8.7×
ICCCImmucell22.1×
INFUInfuSystem12.1×
LFVNLifevantage11.0×
VMDViemed Healthcare12.8×
Peer median16.7×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Coherus Oncology

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.